Zhejiang Jianfeng Group (600668.SH) subsidiary obtains registration certificate for compound tropicamide eye drops.
Jianfeng Group (600668.SH) announced that recently, its wholly-owned subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. received the Drug Registration Certificate for Compound Tropicamide Eye Drops issued by the National Medical Products Administration. Tropicamide is a synthetic derivative of tropic acid, functioning as an M-cholinergic receptor antagonist, similar to atropine. Phenylephrine is an adrenaline receptor agonist, which has a mydriatic effect. This product is used for diagnostic and therapeutic purposes related to mydriasis and cycloplegia.
Zhejiang Jianfeng Group (600668.SH) announced that its wholly-owned subsidiary, Zhejiang Jianfeng Pharmaceutical Co., Ltd., has received the drug registration certificate for Compound Tropicamide Eye Drops approved and issued by the National Medical Products Administration. Tropicamide is a synthetic derivative of tropic acid and is an M-type acetylcholine receptor blocker, acting similarly to atropine. Hydroxydopamine is an adrenaline receptor stimulant that has a mydriatic effect. This product is used for mydriasis and accommodation paralysis for diagnostic and therapeutic purposes.
Related Articles
SINOPEC CORP (00386) invested 4.8019 million yuan on August 3 to repurchase 909,400 A-shares.
GON TECHNOLOGY (02768) cancels 6.25 million shares of inventory A-shares.
Jiangsu Hengrui Pharmaceuticals (01276) spent 33.736 million yuan to repurchase 637,000 A-shares on August 3.
SINOPEC CORP (00386) invested 4.8019 million yuan on August 3 to repurchase 909,400 A-shares.
GON TECHNOLOGY (02768) cancels 6.25 million shares of inventory A-shares.
Jiangsu Hengrui Pharmaceuticals (01276) spent 33.736 million yuan to repurchase 637,000 A-shares on August 3.
RECOMMEND
